{"transactions":[{"id":727723,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:11.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000633","document":"wk-form4_1782338768.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000633/wk-form4_1782338768.xml","form_type":"4"}},{"id":727722,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:11.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":919876,"source":{"system":"sec-edgar","filing":"0001470831-26-000633","document":"wk-form4_1782338768.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000633/wk-form4_1782338768.xml","form_type":"4"}},{"id":729175,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T22:46:04.000Z","date":"2026-06-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":788,"price":66.27,"value":52220.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":915886,"source":{"system":"sec-edgar","filing":"0001470831-26-000569","document":"wk-form4_1782254762.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000569/wk-form4_1782254762.xml","form_type":"4"}},{"id":742907,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:25:30.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001192591-26-000004","document":"form4-06102026_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259126000004/form4-06102026_080626.xml","form_type":"4"}},{"id":789637,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:13:06.000Z","date":"2026-05-04","kind":"gift","planned":false,"acquired":false,"shares":7422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total reflected in Column 5 of Table I includes shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998."}],"balance_after":31113,"source":{"system":"sec-edgar","filing":"0001192591-26-000002","document":"form4-05062026_080559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259126000002/form4-05062026_080559.xml","form_type":"4"}},{"id":991159,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-21T21:24:47.000Z","date":"2025-11-19","kind":"other","planned":false,"acquired":true,"shares":1489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents the receipt by the reporting person of his pro rata share of a distribution made by one or more entities affiliated with Third Rock Ventures, for no consideration, of shares of the Issuer's common stock, which distribution was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended."}],"balance_after":31113,"source":{"system":"sec-edgar","filing":"0001192591-25-000010","document":"form4-11212025_091144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259125000010/form4-11212025_091144.xml","form_type":"4"}},{"id":1013152,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-27T20:46:23.000Z","date":"2025-10-23","kind":"gift","planned":false,"acquired":false,"shares":28423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5."}],"balance_after":29624,"source":{"system":"sec-edgar","filing":"0001192591-25-000008","document":"form4-10272025_081019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259125000008/form4-10272025_081019.xml","form_type":"4"}},{"id":1032912,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T20:15:25.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.67,"expiration_date":"2035-09-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001192591-25-000005","document":"form4-09242025_080916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259125000005/form4-09242025_080916.xml","form_type":"4"}},{"id":1068976,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T23:06:17.000Z","date":"2025-08-11","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":48,"value":2400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025."}],"balance_after":916674,"source":{"system":"sec-edgar","filing":"0000950170-25-107510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025107510/ownership.xml","form_type":"4"}},{"id":1068975,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T23:06:17.000Z","date":"2025-08-08","kind":"sale","planned":true,"acquired":false,"shares":58338,"price":46.6394,"value":2720849.3172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":966674,"source":{"system":"sec-edgar","filing":"0000950170-25-107510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025107510/ownership.xml","form_type":"4"}},{"id":1068974,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T23:06:17.000Z","date":"2025-08-08","kind":"sale","planned":true,"acquired":false,"shares":191662,"price":45.8703,"value":8791593.4386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":1025012,"source":{"system":"sec-edgar","filing":"0000950170-25-107510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025107510/ownership.xml","form_type":"4"}},{"id":1099305,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T21:54:20.000Z","date":"2025-06-27","kind":"gift","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1216674,"source":{"system":"sec-edgar","filing":"0000950170-25-091764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025091764/ownership.xml","form_type":"4"}},{"id":1102686,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T22:56:50.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":8425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":8425,"derivative":{"exercise_price":41.73,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":8425},"source":{"system":"sec-edgar","filing":"0000950170-25-089648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089648/ownership.xml","form_type":"4"}},{"id":1102685,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T22:56:50.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":6589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.  One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1236674,"source":{"system":"sec-edgar","filing":"0000950170-25-089648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089648/ownership.xml","form_type":"4"}},{"id":1284228,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":45638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":45638,"derivative":{"exercise_price":10.42,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":45638},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284227,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46675,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024.  All terms of the option remained unchanged other than the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.08,"expiration_date":"2034-04-22","underlying":"Common Stock","underlying_shares":46675},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284226,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":46675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":46675,"derivative":{"exercise_price":10.42,"expiration_date":"2034-04-22","underlying":"Common Stock","underlying_shares":46675},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284225,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5704,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024.  All terms of the option remained unchanged other than the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.74,"expiration_date":"2033-03-08","underlying":"Common Stock","underlying_shares":5704},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284224,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":5704,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":5704,"derivative":{"exercise_price":10.42,"expiration_date":"2033-03-08","underlying":"Common Stock","underlying_shares":5704},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284223,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80385,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024.  All terms of the option remained unchanged other than the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_price":11.19,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":80385},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284222,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:21.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":80385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2024."}],"balance_after":80385,"derivative":{"exercise_price":10.42,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":80385},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284221,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"8% Convertible Note due 2026","published_at":"2025-02-04T21:35:21.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":false,"price":78961.64,"reported_value":75000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Pursuant to the terms of the Convertible Note (defined below), the conversion price for the principal balance of the Convertible Note and all accrued and unpaid interest thereon was the lesser of:  (i) the share price paid for the issuance of the Issuer's Series C Preferred Stock and (ii) the offering price for the Issuer's next private placement or its initial public offering, in each case subject to a 20% discount.  Accordingly, the Convertible Note was converted into shares of the Issuer's Series D-1 Preferred Stock at a price per share that amounted to 80% of the price at which shares of the Issuer's Series D Preferred Stock were issued."},{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On November 26, 2024 (the \"Conversion Date\"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the \"Convertible Note\"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon.  The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026.  Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On November 26, 2024 (the \"Conversion Date\"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the \"Convertible Note\"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon.  The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026.  Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On November 26, 2024 (the \"Conversion Date\"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the \"Convertible Note\"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon.  The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026.  Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the \"Trust\"), of which the reporting person is the trustee."}],"derivative":{"exercise_price":1.1034,"expiration_date":"2026-12-15","underlying":"Series D-1 Preferred Stock","underlying_shares":71564},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284220,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D-1 Preferred Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":true,"shares":71564,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336.  As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801.  While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date."},{"field":"date","element":"transactionDate","label":"F6","text":"This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). It is reported herein as a transaction pursuant to Rule 16a-2(a).  All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336.  As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801.  While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336.  As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801.  While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336.  As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801.  While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the \"Trust\"), of which the reporting person is the trustee."}],"balance_after":7422,"derivative":{"underlying":"Common Stock","underlying_shares":7422},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284219,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D-1 Preferred Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":71564,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the \"Trust\"), of which the reporting person is the trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7422},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284218,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":169405,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20717},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284217,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":72727,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8807},"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284216,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":7422,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the \"Trust\"), of which the reporting person is the trustee."}],"balance_after":7422,"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284215,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":20717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date."}],"balance_after":58047,"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1284214,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:21.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":8807,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date."}],"balance_after":37330,"source":{"system":"sec-edgar","filing":"0001415889-25-002956","document":"form4-02042025_090216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000141588925002956/form4-02042025_090216.xml","form_type":"4"}},{"id":1469556,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-25T21:38:09.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":26014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer."}],"balance_after":26014,"derivative":{"exercise_price":27.36,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":26014},"source":{"system":"sec-edgar","filing":"0000950170-24-077445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024077445/ownership.xml","form_type":"4"}},{"id":1629465,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-21T21:04:30.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0000950170-24-017894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024017894/ownership.xml","form_type":"4"}},{"id":1629464,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T21:04:30.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1509,"price":37.21,"value":56149.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1230085,"source":{"system":"sec-edgar","filing":"0000950170-24-017894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024017894/ownership.xml","form_type":"4"}},{"id":1629463,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T21:04:30.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 838 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1231594,"source":{"system":"sec-edgar","filing":"0000950170-24-017894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024017894/ownership.xml","form_type":"4"}},{"id":1734711,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-11-20T21:00:22.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":3760,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0001209191-23-056011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123056011/doc4.xml","form_type":"4"}},{"id":1734710,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T21:00:22.000Z","date":"2023-11-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1301,"price":28.86,"value":37546.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1226996,"source":{"system":"sec-edgar","filing":"0001209191-23-056011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123056011/doc4.xml","form_type":"4"}},{"id":1734709,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T21:00:22.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1228297,"source":{"system":"sec-edgar","filing":"0001209191-23-056011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123056011/doc4.xml","form_type":"4"}},{"id":1801964,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-08-18T20:00:15.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":7520,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0001209191-23-046514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123046514/doc4.xml","form_type":"4"}},{"id":1801963,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-18T20:00:15.000Z","date":"2023-08-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1301,"price":29.8,"value":38769.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1224537,"source":{"system":"sec-edgar","filing":"0001209191-23-046514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123046514/doc4.xml","form_type":"4"}},{"id":1801962,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-18T20:00:15.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,251 shares acquired on August 15, 2023 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1225838,"source":{"system":"sec-edgar","filing":"0001209191-23-046514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123046514/doc4.xml","form_type":"4"}},{"id":1845283,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:20:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":51501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":51501,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":51501},"source":{"system":"sec-edgar","filing":"0001209191-23-039380","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123039380/doc4.xml","form_type":"4"}},{"id":1886919,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-18T20:05:30.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":false,"shares":3759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":11280,"derivative":{"underlying":"Common Stock","underlying_shares":3759},"source":{"system":"sec-edgar","filing":"0001209191-23-030593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123030593/doc4.xml","form_type":"4"}},{"id":1886918,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-18T20:05:30.000Z","date":"2023-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1300,"price":14.09,"value":18317.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,759 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1220827,"source":{"system":"sec-edgar","filing":"0001209191-23-030593","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123030593/doc4.xml","form_type":"4"}},{"id":1886917,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-18T20:05:30.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":true,"shares":3759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1222127,"source":{"system":"sec-edgar","filing":"0001209191-23-030593","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123030593/doc4.xml","form_type":"4"}},{"id":2003679,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-22T01:18:09.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."}],"balance_after":15039,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0001209191-23-011452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123011452/doc4.xml","form_type":"4"}},{"id":2003678,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-22T01:18:09.000Z","date":"2023-02-16","kind":"tax_withholding","acquired":false,"shares":1534,"price":12.64,"value":19389.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1218368,"source":{"system":"sec-edgar","filing":"0001209191-23-011452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123011452/doc4.xml","form_type":"4"}},{"id":2003677,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-22T01:18:09.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,891 shares acquired on February 15, 2023 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1219902,"source":{"system":"sec-edgar","filing":"0001209191-23-011452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123011452/doc4.xml","form_type":"4"}},{"id":2110389,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-11-18T23:36:58.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."}],"balance_after":18799,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0001209191-22-057982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122057982/doc4.xml","form_type":"4"}},{"id":2110388,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T23:36:58.000Z","date":"2022-11-16","kind":"tax_withholding","acquired":false,"shares":1301,"price":9.64,"value":12541.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1214251,"source":{"system":"sec-edgar","filing":"0001209191-22-057982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122057982/doc4.xml","form_type":"4"}},{"id":2110387,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T23:36:58.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 840 shares acquired on February 17, 2021 and 1,497 shares acquired on August 15, 2022 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1215552,"source":{"system":"sec-edgar","filing":"0001209191-22-057982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122057982/doc4.xml","form_type":"4"}},{"id":2179611,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-18T22:33:30.000Z","date":"2022-08-16","kind":"exercise","acquired":false,"shares":3760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."}],"balance_after":22559,"derivative":{"underlying":"Common Stock","underlying_shares":3760},"source":{"system":"sec-edgar","filing":"0001209191-22-046731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122046731/doc4.xml","form_type":"4"}},{"id":2179610,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T22:33:30.000Z","date":"2022-08-16","kind":"tax_withholding","acquired":false,"shares":1287,"price":11.08,"value":14259.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1209455,"source":{"system":"sec-edgar","filing":"0001209191-22-046731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122046731/doc4.xml","form_type":"4"}},{"id":2179609,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T22:33:30.000Z","date":"2022-08-16","kind":"exercise","acquired":true,"shares":3760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1210742,"source":{"system":"sec-edgar","filing":"0001209191-22-046731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122046731/doc4.xml","form_type":"4"}},{"id":2222111,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:30:37.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":104921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":104921,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":104921},"source":{"system":"sec-edgar","filing":"0001209191-22-039249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122039249/doc4.xml","form_type":"4"}},{"id":2265805,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-18T20:05:42.000Z","date":"2022-05-16","kind":"exercise","acquired":false,"shares":3759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."}],"balance_after":26319,"derivative":{"underlying":"Common Stock","underlying_shares":3759},"source":{"system":"sec-edgar","filing":"0000899243-22-018590","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322018590/doc4.xml","form_type":"4"}},{"id":2265804,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:42.000Z","date":"2022-05-16","kind":"tax_withholding","acquired":false,"shares":1541,"price":6.74,"value":10386.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,759 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":1206982,"source":{"system":"sec-edgar","filing":"0000899243-22-018590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322018590/doc4.xml","form_type":"4"}},{"id":2265803,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:42.000Z","date":"2022-05-16","kind":"exercise","acquired":true,"shares":3759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1208523,"source":{"system":"sec-edgar","filing":"0000899243-22-018590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322018590/doc4.xml","form_type":"4"}},{"id":2333412,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-15T21:34:23.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":30078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date."}],"balance_after":30078,"derivative":{"underlying":"Common Stock","underlying_shares":30078},"source":{"system":"sec-edgar","filing":"0000899243-22-011086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322011086/doc4.xml","form_type":"4"}},{"id":2483831,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-07T01:58:03.000Z","date":"2021-12-02","kind":"grant","acquired":true,"shares":55011,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55011,"derivative":{"exercise_price":40.03,"exercise_date":"2022-12-02","expiration_date":"2031-12-01","underlying":"Common Stock","underlying_shares":55011},"source":{"system":"sec-edgar","filing":"0000899243-21-047032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321047032/doc4.xml","form_type":"4"}},{"id":2649584,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T00:37:03.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":13286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":13286,"derivative":{"exercise_price":28.2,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":13286},"source":{"system":"sec-edgar","filing":"0001209191-21-044176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000120919121044176/doc4.xml","form_type":"4"}},{"id":2658958,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T23:16:29.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":38895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":38895,"derivative":{"exercise_price":62.63,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":38895},"source":{"system":"sec-edgar","filing":"0000899243-21-025398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321025398/doc4.xml","form_type":"4"}},{"id":2814209,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T21:05:21.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":524,"price":71.91,"value":37680.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the grant and issuance of 1,521 vested shares of Common Stock."}],"balance_after":1204764,"source":{"system":"sec-edgar","filing":"0000899243-21-009369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321009369/doc4.xml","form_type":"4"}},{"id":2814208,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T21:05:21.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":1521,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1205288,"source":{"system":"sec-edgar","filing":"0000899243-21-009369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321009369/doc4.xml","form_type":"4"}},{"id":2894957,"issuer":{"id":136038,"kind":"organization","name":"Population Health Investment Co., Inc.","symbol":"PHIC"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2021-01-27T01:45:24.000Z","date":"2021-01-26","kind":"other","acquired":true,"shares":43125,"price":250,"value":10781250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading \"Description of Securities--Founder Shares\", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading \"Description of Securities--Founder Shares\", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading \"Description of Securities--Founder Shares\", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share."}],"balance_after":43125,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":43125},"source":{"system":"sec-edgar","filing":"0000899243-21-003403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000089924321003403/doc4.xml","form_type":"4"}},{"id":3004198,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-20T01:14:40.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":10256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":260207,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":10256},"source":{"system":"sec-edgar","filing":"0000899243-20-028659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320028659/doc4.xml","form_type":"4"}},{"id":3004197,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-10-20T01:14:40.000Z","date":"2020-10-16","kind":"sale","acquired":false,"shares":10256,"price":41,"value":420496.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."}],"balance_after":1203767,"source":{"system":"sec-edgar","filing":"0000899243-20-028659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320028659/doc4.xml","form_type":"4"}},{"id":3004196,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-10-20T01:14:40.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":10256,"price":17,"value":174352.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."}],"balance_after":1214023,"source":{"system":"sec-edgar","filing":"0000899243-20-028659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320028659/doc4.xml","form_type":"4"}},{"id":3018669,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T20:05:08.000Z","date":"2020-09-30","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":270463,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-026658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026658/doc4.xml","form_type":"4"}},{"id":3018668,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-10-01T20:05:08.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":10000,"price":38,"value":380000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."}],"balance_after":1203767,"source":{"system":"sec-edgar","filing":"0000899243-20-026658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026658/doc4.xml","form_type":"4"}},{"id":3018667,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-10-01T20:05:08.000Z","date":"2020-09-30","kind":"exercise","acquired":true,"shares":10000,"price":17,"value":170000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."}],"balance_after":1213767,"source":{"system":"sec-edgar","filing":"0000899243-20-026658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026658/doc4.xml","form_type":"4"}},{"id":3020824,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-09-29T23:02:42.000Z","date":"2020-09-29","kind":"sale","acquired":false,"shares":18200,"price":37.5,"value":682500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."}],"balance_after":1203767,"source":{"system":"sec-edgar","filing":"0000899243-20-026476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026476/doc4.xml","form_type":"4"}},{"id":3020823,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-09-29T23:02:42.000Z","date":"2020-09-25","kind":"sale","acquired":false,"shares":15396,"price":37.4685,"value":576865.026,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $37.26 to $37.66 per share."}],"balance_after":1221967,"source":{"system":"sec-edgar","filing":"0000899243-20-026476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026476/doc4.xml","form_type":"4"}},{"id":3020822,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-09-29T23:02:42.000Z","date":"2020-09-25","kind":"sale","acquired":false,"shares":65661,"price":36.6822,"value":2408589.9342,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $36.26 to $37.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1237363,"source":{"system":"sec-edgar","filing":"0000899243-20-026476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026476/doc4.xml","form_type":"4"}},{"id":3122273,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-04T23:21:00.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":112422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":112422,"derivative":{"exercise_price":29,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":112422},"source":{"system":"sec-edgar","filing":"0000899243-20-015306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320015306/doc4.xml","form_type":"4"}},{"id":3180860,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-04-07T20:06:39.000Z","date":"2020-04-03","kind":"gift","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1302291,"source":{"system":"sec-edgar","filing":"0000899243-20-010392","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320010392/doc4.xml","form_type":"4"}},{"id":3277242,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-02-13T00:03:08.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":20000,"price":36,"value":720000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019."}],"balance_after":1342291,"source":{"system":"sec-edgar","filing":"0000899243-20-004375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320004375/doc4.xml","form_type":"4"}},{"id":3309676,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-17T00:17:51.000Z","date":"2020-01-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":280463,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-001340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320001340/doc4.xml","form_type":"4"}},{"id":3309675,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-01-17T00:17:51.000Z","date":"2020-01-14","kind":"sale","acquired":false,"shares":10000,"price":35,"value":350000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019."}],"balance_after":1362291,"source":{"system":"sec-edgar","filing":"0000899243-20-001340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320001340/doc4.xml","form_type":"4"}},{"id":3309674,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2020-01-17T00:17:51.000Z","date":"2020-01-14","kind":"exercise","acquired":true,"shares":10000,"price":17,"value":170000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 865 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1372291,"source":{"system":"sec-edgar","filing":"0000899243-20-001340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320001340/doc4.xml","form_type":"4"}},{"id":3341081,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-17T02:00:10.000Z","date":"2019-12-12","kind":"grant","acquired":true,"shares":82878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":82878,"derivative":{"exercise_price":37.45,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":82878},"source":{"system":"sec-edgar","filing":"0000899243-19-029348","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319029348/doc4.xml","form_type":"4"}},{"id":3468347,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Management Incentive Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":290476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":290476},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468346,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Management Incentive Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":418016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":418016},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468345,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Management Incentive Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":406723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":406723},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468344,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Series B Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":66729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":66729},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468343,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":132317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":132317},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468342,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Units","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":47165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47165},"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468341,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":290476,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":1361426,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468340,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":418016,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":1070950,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468339,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":406723,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person.  The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":652934,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468338,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":66729,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":246211,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468337,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":132317,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":179482,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3468336,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of Pharmaceuticals"}}],"security":"Common Stock","published_at":"2019-07-03T20:12:37.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":47165,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all units in BridgeBio Pharma LLC (the \"LLC\") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\").  In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share.  The LLC units have no expiration date."}],"balance_after":47165,"source":{"system":"sec-edgar","filing":"0000899243-19-019138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019138/doc4.xml","form_type":"4"}},{"id":3571792,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-04-01T19:27:18.000Z","date":"2019-03-28","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan."}],"balance_after":10000,"derivative":{"exercise_price":33.59,"expiration_date":"2029-03-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-022070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119022070/doc4.xml","form_type":"4"}},{"id":3703590,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T17:46:44.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":11481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":0,"derivative":{"exercise_price":5.1,"exercise_date":"2009-06-09","expiration_date":"2019-06-09","underlying":"Common Stock","underlying_shares":11481},"source":{"system":"sec-edgar","filing":"0001209191-19-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119002183/doc4.xml","form_type":"4"}},{"id":3703589,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T17:46:44.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":14835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":0,"derivative":{"exercise_price":5.1,"exercise_date":"2009-02-25","expiration_date":"2019-02-24","underlying":"Common Stock","underlying_shares":14835},"source":{"system":"sec-edgar","filing":"0001209191-19-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119002183/doc4.xml","form_type":"4"}},{"id":3703588,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T17:46:44.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":19607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":0,"derivative":{"exercise_price":5.1,"exercise_date":"2009-02-25","expiration_date":"2019-02-24","underlying":"Common Stock","underlying_shares":19607},"source":{"system":"sec-edgar","filing":"0001209191-19-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119002183/doc4.xml","form_type":"4"}},{"id":3703587,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-04T17:46:44.000Z","date":"2019-01-02","kind":"exercise","acquired":true,"shares":45923,"price":5.1,"value":234207.3,"ownership":{"direct":false,"nature":"Charles Homcy Revocable Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":165403,"source":{"system":"sec-edgar","filing":"0001209191-19-002183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119002183/doc4.xml","form_type":"4"}},{"id":3724550,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-19T19:07:47.000Z","date":"2018-12-19","kind":"exercise","acquired":false,"shares":25782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":0,"derivative":{"exercise_price":4.1,"exercise_date":"2008-12-23","expiration_date":"2018-12-22","underlying":"Common Stock","underlying_shares":25782},"source":{"system":"sec-edgar","filing":"0001209191-18-063579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118063579/doc4.xml","form_type":"4"}},{"id":3724549,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-19T19:07:47.000Z","date":"2018-12-17","kind":"exercise","acquired":false,"shares":39828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2018."}],"balance_after":25782,"derivative":{"exercise_price":4.1,"exercise_date":"2008-12-23","expiration_date":"2018-12-22","underlying":"Common Stock","underlying_shares":39828},"source":{"system":"sec-edgar","filing":"0001209191-18-063579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118063579/doc4.xml","form_type":"4"}},{"id":3724548,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-19T19:07:47.000Z","date":"2018-12-17","kind":"exercise","acquired":false,"shares":24390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.1,"exercise_date":"2008-12-23","expiration_date":"2018-12-22","underlying":"Common Stock","underlying_shares":24390},"source":{"system":"sec-edgar","filing":"0001209191-18-063579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118063579/doc4.xml","form_type":"4"}},{"id":3724547,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-19T19:07:47.000Z","date":"2018-12-19","kind":"exercise","acquired":true,"shares":25782,"price":4.1,"value":105706.2,"ownership":{"direct":false,"nature":"Charles Homcy Revocable Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Dr. Homcy exercised these shares through a cash exercise and transferred the shares following the exercise into the Charles Homcy Revocable Trust for which Dr. Homcy is a trustee."}],"balance_after":119480,"source":{"system":"sec-edgar","filing":"0001209191-18-063579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118063579/doc4.xml","form_type":"4"}}],"next_cursor":"2018-12-19T19:07:47.000000Z,3724547"}